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A B S T R A C T
Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) is a rare platelet disorder caused by mutations in RUNX1. We generated an iPSC line
(GENYOi005-A) from a FPDMM patient with a non-previously reported variant p.Thr196Ala. Non-integrative Sendai viruses expressing the Yamanaka repro-
gramming factors were used to reprogram peripheral blood mononuclear cells from this FPDMM patient. Characterization of GENYOi005-A included genetic analysis
of RUNX1 locus, Short Tandem Repeats proﬁling, alkaline phosphatase enzymatic activity, expression of pluripotency-associated factors and diﬀerentiation studies in
vitro and in vivo. This iPSC line will provide a powerful tool to study developmental alterations of FPDMM patients.
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1. Resource utility
GENYOi005-A is an iPSC line generated from a Familial platelet
disorder with associated myeloid malignancy (FPDMM) patient with
this new variant p.Thr196Ala in RUNX1. This cell line will be a very
useful tool to understand hematopoiesis development and leukemo-
genesis of this RUNX1 variant.
2. Resource details
Familial platelet disorder with associated myeloid malignancy
(FPDMM) is an autosomal dominant disease of the hematopoietic
system caused by heterozygous mutations in RUNX1 (OMIM#601399).
FPDMM is characterized by thrombocytopenia, abnormal platelet
function and an increased risk of developing other blood disorders or
cancers such as myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML) (Sakurai et al., 2016). iPSCs lines from this pathology
have been previously obtained (Sakurai et al., 2014). In this study, we
report the generation of a new cellular line from peripheral blood
mononuclear cells (PBMCs) obtained from a FPDMM patient carrying a
non-previously reported variant (p.Thr196Ala) in the RUNX1 locus,
which was identiﬁed by our next-generation sequencing panel
(Bastida et al., 2018).
CytoTune iPS 2.0 Sendai Reprogramming kit (ThermoFisher
Scientiﬁc) was used to reprogram PBMCs from the FDPMM patient.
PBMCs were transduced with Sendai virus (SeV) vectors expressing and
delivering the reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC.
2–3 weeks after viral exposure several clones were selected and char-
acterized as described below.
Firstly, the presence of the variant p.Thr196Ala in the exon 6 of the
RUNX1 locus in the GENYOi005-A cell line was conﬁrmed by Sanger
sequencing. As shown in Fig. 1A, PBMCs from the patient (FPD-PBMCs)
and GENYOi005-A cells share the same heterozygous variant. Short
Tandem Repeat polymorphism (STR) analysis conﬁrmed the same ge-
netic identity between both samples. GENYOi005-A silenced the ex-
pression of exogenous reprogramming transgenes (Fig. 1B) and acti-
vated the expression of the endogenous pluripotent transcription factors
(SOX2, REX1, NANOG and OCT4) (Fig. 1C). Importantly, GENYOi005-A
cells showed normal karyotype (46, XX) (Fig. 1D) and alkaline phos-
phatase activity (Fig. 1E). In addition, expression of the pluripotent
markers SSEA3, SSEA4, Tra1-60, Tra1-81 and Oct3/4 was conﬁrmed by
ﬂow cytometry analysis (Fig. 1F). Moreover, mycoplasma analysis was
negative for GENYOi005-A cell line.
Finally, to demonstrate the capacity of GENYOi005-A to diﬀer-
entiate into the three germ layers in vitro and in vivo, embryoid bodies
(EBs) formation assays (Fig. 1G) and teratoma formation assays were
accomplished (Fig. 1H). EBs and teratomas derived from this cell line
showed speciﬁc structures from endoderm (ciliated epithelium), me-
soderm (cartilage) and ectoderm (neural rosettes). Besides, we also
detected the expression of representative markers of the three germ
layers: ectoderm (β3-Tubulin), mesoderm (Vimentin) and endoderm
(Cytokeratin CKAE1-AE) (Table 1).
3. Materials and methods
3.1. Reprogramming of GENYOi005-A line
The peripheral blood sample was obtained from a woman with
FPDMM after informed consent according to the Local Ethical
Committee of the Instituto de Investigación Biomédica (IBSAL,
Salamanca, Spain), the Andalusian Ethics Review Board for Cellular
Reprogramming requirements and with Spanish and EU legislation.
PBMCs from the patient were isolated by centrifugation using Ficoll
Paque™ PLUS (GE Healthcare) and cultured for four days in
StemSpan™ SFEM (StemCell Technologies) supplemented with
hSCF, hFLT3L, hIL6 and hIL3 (Peprotech). Then, 3 million PBMCs
were transduced with Sendai virus (SeV) using CytoTune®-iPS 2.0
Reprogramming kit (Life Technologies, Invitrogen) and plated over
12-well ﬁbronectin-coated plate (BD BioCoat™) as formerly de-
scribed (Lopez-Onieva et al., 2016). Four weeks after reprogram-
ming, GENYOi005-A cells were accommodated to grow in Essential
8 medium (E8) on Matrigel (BD Bioscience). GENYOi005-A cells
were split weekly at a ratio of 1:8 using PBS/EDTA (0.5 mM) and
cultured at 37 °C, 5% CO2.
3.2. Mutational analysis
Genomic DNA was isolated from PBMCs of the FPDMM patient,
GENYOi005-A line and a healthy control iPSC line (PBMC1-iPS4F1)
using the DNA extraction kit (Qiagen). PCR ampliﬁcation was per-
formed in all samples using a set of primers that recognizes RUNX1
exon 6 (Set RUNX1, Table 2) following the manufacturer's instructions
in a SureCycler 8800 thermal cycler (Agilent). Ampliﬁed fragments
were run and sequenced using RUNX1 Forward primer, in an ABI 3130
genetic analyzer (Applied Biosystems, Life Technologies).
3.3. Short Tandem Repeat polymorphism (STR) proﬁling
The genetic signature of FPDMM-PBMCs and GENYOi005-A cell line
was determined as previously described (Lopez-Onieva et al., 2016).
This information is available with the authors.
3.4. RT-PCR analysis
Total RNA from GENYOi005-A cell line, the control PBMC1-
iPS4F1line and PBMCs from FPDMM patient was isolated with the High
pure RNA isolation kit (Roche) and cDNA was produced with the
Transcription First Strand c-DNA synthesis kit (Roche) according to the
manufacturer's instructions. PCR was performed using GoTaq Flexi
DNA Polimerase kit (Promega) in a SureCycler 8800 thermal cycler
(Agilent). PCR fragments were visualized in an agarose gel. SeV, KLF4,
c-MYC and KOS primer sets were used to analyse the presence of exo-
genous genes and Oct3/4, SOX2, NANOG, REX1 and β-ACTIN primer
sets used to verify the expression of pluripotency markers as previously
described (Montes et al., 2019). FPDMM-PBMCs transduced cells at day
4 subsequent to SeV exposure was used as a positive control and
PBMC1-iPS4F1line as a negative control for exogenous reprogramming
factors. For endogenous pluripotent transcription factors, PBMC1-
iPS4F1 iPSC line was used as a positive control and FPDMM-PBMCs as a
negative control. Primer sequences used are shown in Table 2.
3.5. Karyotyping
Chromosomal analysis of GENYOi005-A line at passage 13 was ac-
complished by GTG-banding analysis at the Andalusian Public Health
System Biobank (Spain). 20 metaphases were evaluated following the
International System Cytogenetics Nomenclature recommendations.
3.6. Alkaline phosphatase
After ﬁve days in culture on a 24-well plate (Corning), GENYOi005-
A colonies were assayed for phosphatase alkaline enzymatic activity
using Alkaline Phosphatase detection kit (Merck-Millipore) following
manufacturer's instructions.
3.7. Flow cytometry analysis
GENYOi005-A cell line colonies were dissociated with Tryple
Express (Life Technologies) and cell suspension was stained with SSEA3
(PE, BioScience), SSEA4 (Alexa Fluor® 647, BD Pharmingen), Tra1-60
(PE, BioScience) and Tra1-81 (Alexa Fluor® 647, BD Pharmingen) an-
tibodies for 20min. Intracellular staining for Oct3/4 was performed by
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Fig. 1. Characterization of GENYOi005-A cell line (A) Sequence analysis of the variant p.Thr196Ala in exon 6 of the RUNX1 from healthy control PBMCs and iPSC
line (PBMC1-iPS4F1) (left panels) and FPDMM patient PBMCs and GENYOi005-A cell line (right panels). (B) RT-PCR analysis conﬁrmed the silencing of exogenous
reprogramming factors and SeV vector. PBMCs transduced cells from the patient at day 4 after Sendai virus exposure were used as a Positive Control. Non-transduced
PBMCs from the patient were used as a Negative Control. (C) Expression of the endogenous pluripotent transcription factors SOX2, REX1, NANOG and OCT 3 was
assessed by RT-PCR. PBMC1-iPS4F1 cell line was used as Positive Control. (D) GTG-banding shows a normal karyotype in GENYOi005-A cell line. (E) Representative
colonies of GENYOi005-A cell line growing in E8 medium (left pictures). Alkaline phosphatase enzymatic activity staining in GENYOi005-A colonies (right pictures)
(Scale bar=150 µm). (F) Protein expression of pluripotency-associated markers SSEA3, SSEA4, TRA1-81, TRA 1-60 and OCT3/4 by FACS analysis. The inset shows
the staining of the isotype-matched antibody. (G) Embryo body (EB) diﬀerentiation assay for pluripotency. Immunohistochemistry analysis for endoderm (CKAE1-
AE3), mesoderm (Vimentin) and ectoderm (β-III-Tubulin) from 3-week EBs. (Scale bar = 150 µm) (H) In vivo diﬀerentiation test by teratoma formation assay.
Histological sections from 10-week teratomas developed in the dorsal ﬂanks of NOD/LtSz-scid interleukin-2Rγ-/- mice after injecting 2 million GENYOi005-A cells.
Hematoxylin and eosin (H&E) staining allowed us to identify several morphological structures characteristics for each germ layer: Ciliated Epithelium (Endoderm),
Cartilage (Mesoderm) and Neural Rosette (Ectoderm). In the right panels, immunohistochemistry analysis conﬁrmed diﬀerentiation to endoderm (CK-AE1-AE3),
mesoderm (Vimentin) and ectoderm (GFAP). (Scales bar from 50–250 µm).
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Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography Normal Fig. 1 panel E
Phenotype Qualitative analysis (RT-PCR) Positive for SOX2, REX1, NANOG and OCT4 Fig. 1 panel C
(Alkaline Phosphatase staining) Positive Fig. 1 panel E
Quantitative analysis (Flow
cytometry)
Oct3/4: 79% Fig. 1 panel F
Tra1-60: 78%
Tra1-81: 80%
SSEA-4: 93%
SSEA-3: 37%
Genotype Karyotype (G-banding) and
resolution
46, XX Resolution 450–500 Fig. 1 panel D
Identity STR analysis 16 loci tested, all matched Available with the authors
Mutation analysis (IF APPLICABLE) Sequencing Heterozygous mutation Fig. 1 panel A
Southern Blot OR WGS
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR
Negative
Supplementary ﬁle 2
Diﬀerentiation potential Embryoid body formation
Teratoma formation
Immunohistochemistry for Vimentin, CK-AE1-AE3, β-III-
tubulin
Fig. 1 panel G
Immunohistochemistry for Vimentin, CK-AE1-AE3, GFAP Fig. 1 panel H
Donor screening (OPTIONAL) HIV 1+2 Hepatitis B, Hepatitis C Negative Not shown but available with author
Genotype additional info (OPTIONAL) Blood group genotyping N/A
HLA tissue typing N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti SSEA3-PE 1:100 eBioscience Cat# 12-8833-42
RRID:AB_10854121
Pluripotency Markers Rabbit anti-SSEA4-PE 1:100 BD Pharmingen Cat# 560128
RRID:AB_1645533
Pluripotency Markers Rabbit anti-Tra1-60-PE 1:100 eBioscience Cat# 12-8863-82
RRID:AB_891602
Pluripotency Markers Rabbit anti-Tra1-81-PE 1:100 BD BioScience Cat# 560161
RRID:AB_1645540
Pluripotency Markers Mouse anti-OCT4 1:100 BD BioScience Cat# 611203
RRID:AB_398737
Secondary antibodies Goat Anti-Mouse IgG/IgM FITC 1:200 BD BioScience Cat# 554001
RRID:AB_395197
Isotype control PE Mouse IgM, PE conjugated 1:100 BD BioScience Cat# 555584
RRID:AB_395960
Diﬀerentiation Markers Mouse Anti-CKAE1-AE3 1:50 DAKO Cat # M3515
RRID:AB_2132885
Diﬀerentiation Markers Mouse Anti-Vimentin (V9) Ready to use Roche Tissue Diagnostics
Cat # 790-2917 RRID: N/A
Diﬀerentiation Markers Mouse Anti-β-III-Tubulin 1:50 Millipore Cat # MAB1637
RRID:AB_2210524
Primers
Target Forward/Reverse primer (5′−3′)
Sendai Virus Plasmids (RT-PCR) SeV (181 bp) Forward: GGATCACTAGGTGATATCGAGC
Reverse: ACCAGACAAGAGTTTAAGAGATATGTATC
Sendai Virus KOS Plasmid (RT-PCR) KOS (528 bp) Forward: ATGCACCGCTACGACGTGAGCGC
Reverse: ACCTTGACAATCCTGATGTGG
Sendai Virus c-MYC Plasmid (RT-PCR) c-MYC (532 bp) Forward: TAACTGACTAGCAGGCTTGTCG
Reverse: TCCACATACAGTCCTGGATGATGATG
Sendai Virus KLF4 Plasmid (RT-PCR) KLF4 (410 bp) Forward: TTCCTGCATGCCAGAGGAGCCC
Reverse: AATGTATCGAAGGTGCTCAA
Targeted mutation analysis:
exon speciﬁc PCR
RUNX1 Forward: GGCCACCAACCTCATTCTGT
Reverse:ACTTTTTGGCTTTACGGGGG
Pluripotency Markers (RT-PCR) NANOG (96 bp) Forward: TGCAGTTCCAGCCAAATTCTC
Reverse: CCTAGTGGTCTGCTGTATTACATTAAGG
Pluripotency Markers (RT-PCR) OCT4 (110 bp) Forward: AGTGAGAGGCAACCTGGAGA
Reverse: ACACTCGGACCACATCCTTC
Pluripotency Markers (RT-PCR) REX1(306 bp) Forward: CAGATCCTAAACAGCTCGCAGAAT
Reverse: GCGTACGCAAATTAAAGTCCAGA
Pluripotency Markers (RT-PCR) SOX2 (80 bp) Forward: TCAGGAGTTGTCAAGGCAGAGAAG
Reverse: CTCAGTCCTAGTCTTAAAGAGGCAGC
House-Keeping Gene (RT-PCR) β-ACTIN (165 bp) Forward: CTGGAACGGTGAAGGTGACA
Reverse: AAGGGACTTCCTGTAACAATGCA
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several incubations of 15min using ﬁxation and permeabilization so-
lutions (A and B Fix and Perm Solutions (BD BioScience)). Then,
GENYOi005-A cells were incubated with Oct3/4 (BD BioScience) pri-
mary antibody, and subsequently with FITC-conjugated secondary an-
tibody (BD BioScience). An isotype-match antibody was used as a ne-
gative control. Viable cells were identiﬁed with 7-aminoactinomycin D
staining and were analyzed in the BD FACSVerse™ ﬂow cytometer (BD
Bioscience) using BD FACSuite™ software (BD Bioscience) for acquisi-
tion and FlowJo™ for analysis (FlowJo, LLC-BD Bioscience).
3.8. Embryo body (EB) diﬀerentiation assay
GENYOi005-A colonies were gently scraped oﬀ the ﬂask after
treatment with collagenase IV (Invitrogen), re-suspended into Essential
6 medium (E6) after centrifugation, transferred into low attachment 6-
well plates (Corning) and cultured in an incubator at 37 °C, 5% CO2.
After 16 days, EBs were collected, ﬁxed, embedded in paraﬃn and
sectioned for histological and immunocytochemistry analysis.
Sectioned EBs were stained with hematoxylin and eosin (H&E) for
histological analysis. Immunocytochemistry analysis was performed in
the Pathology Department of the University Hospitals of Granada.
Brieﬂy, antigen retrieval was done by boiling sections for 20 min at
95 °C in citrate buﬀer (pH=6) in a PT-Module (ThermoScientiﬁc). The
Master Polymer Plus Detection System (Peroxidase) (Master
Diagnostica) was used as a visualization system following manufac-
turer's instructions, in an Autostainer 480 S-2D automatic im-
munostainer (ThermoScientiﬁc). Diaminobenzidine (DAB) was used as
the chromogen. Primary antibodies for β-III-Tubulin (ectoderm),
Vimentin (mesoderm) and CKAE1-EA3 (endoderm) are included in
Table 2.
3.9. In vivo teratoma formation
GENYOi005-A cells were dissociated with collagenase IV
(Invitrogen) and resuspended in PBS with 30% Matrigel. 2 million cells
were subcutaneously injected into the dorsal ﬂanks of NOD/LtSz-scid
interleukin-2Rγ_/_ mice (The Jackson Laboratory). At week 10 post-
implantation, teratomas were collected, ﬁxed in formaldehyde, em-
bedded in paraﬃn, sectioned and stained with H&E for histological
analysis. Immunocytochemistry analysis for CKAE1-AE3 (endoderm),
Vimentin (mesoderm) and β-III-Tubulin (ectoderm) was performed on
sectioned slides as described above.
3.10. Mycoplasma analysis
Mycoplasma test for GENYOi005-A cell line was performed by
quantitative PCR analysis (Venor GeM-qEP, Minerva Biolabs) at the
Genomics and Genotyping Unit in GENyO, Spain.
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